Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach

Summary Prostaglandins are considered to play important roles in gastric mucosal protection. The rate-limiting enzyme involved in the biosynthesis of prostaglandins is cyclooxygenase (COX), also known as prostaglandin H synthase. Two forms of COX are known: a constitutively expressed form (COX-1) and a newly-characterized, inducible form (COX-2). In the present study, the immunocytochemical localization of COX-1 and COX-2 was examined in the rat gastrointestinal tract. A strong immunoreactivity for COX-1 was localized in the mucous neck cells of gastric gland. A weak reactivity for COX-1 was also found in the mucous cell types in the cardiac gland and pyloric gland of the stomach as well as in the Brunner's gland of duodenum. Ultrastructurally, the immunoreactivity was localized to the apical cytoplasm of these cells. On the other hand, immunoreactivity for COX-2 was distributed in the surface mucous cells in both the fundic and pyloric regions of stomach. These results suggest that a subset of mucous cells is the primary site for production of prostaglandins in the rat gastrointestinal tract, and that two forms of COX are expressed in distinct types of mucous cell.     

多药耐药基因的转录调控与治疗学机会

人肿瘤多药耐药mdr-1基因的转录调控机制复杂。多个正调控和负调控元件与转录因子的相互作用、表遗传学因素的参与等共同决定着人mdr-1基因表达的组织、细胞和刺激的特异性和依赖性。同时,也为特异或相对特异性地防止／抑制肿瘤细胞的mdr-1基因表达、克服肿瘤多药耐药性提供了基础。新抗肿瘤药物沙尔威辛和ET-743有力地诠释了控制mdr-1基因转录所蕴藏的治疗学机会。     

Developmental regulation of rat brain/Hep G2 glucose transporter gene expression

The developmental regulation of rat brain-derived/Hep G2 glucose transporter gene expression was studied by means of Northern blot hybridization, using a rat brain glucose transporter cDNA probe, in order to directly quantify steady state glucose transporter mRNA levels. The results obtained showed different tissue-specific patterns of glucose transporter mRNA levels during ontogenesis; while in brain there was a sustained increase in the levels of the message from 20 days embryogenesis until 50 days postnatal, other organs such as heart, lung, liver, and muscle expressed maximal levels of the glucose transporter mRNA in 20-day fetuses and 1-day neonates, decreasing subsequently to very low levels. The relative expression of the glucose transporter mRNA in the different tissues, at both fetal and adult stages, was analyzed using a solution hybridization-RNase protection assay. This approach revealed that, while the heart expresses the highest levels of glucose transporter mRNA at 20 days of fetal life, the brain shows the highest levels at the adult stage. These results indicate a tissue-specific ontogenic pattern of glucose transporter gene expression, suggesting a developmental role for this glucose transporter gene product.